Last edition
News about "hyperviscosity syndrome"
FDA Updates Winrevair Label With Phase 3 HYPERION Data
Merck’s Winrevair label has been updated by the US FDA to include data from the Phase 3 HYPERION trial in recently diagnosed adults with pulmonary arterial hypertension.
Hyperviscosity Syndrome | 23/09/2026 | By News Bureau | 110
WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension
Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.
Hyperviscosity Syndrome | 29/10/2025 | By Dineshwori | 423
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy